1. Home
  2. CASH vs SUPN Comparison

CASH vs SUPN Comparison

Compare CASH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASH
  • SUPN
  • Stock Information
  • Founded
  • CASH 1954
  • SUPN 2005
  • Country
  • CASH United States
  • SUPN United States
  • Employees
  • CASH N/A
  • SUPN N/A
  • Industry
  • CASH Major Banks
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CASH Finance
  • SUPN Health Care
  • Exchange
  • CASH Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • CASH 1.9B
  • SUPN 1.9B
  • IPO Year
  • CASH N/A
  • SUPN 2012
  • Fundamental
  • Price
  • CASH $80.39
  • SUPN $35.79
  • Analyst Decision
  • CASH Hold
  • SUPN Hold
  • Analyst Count
  • CASH 3
  • SUPN 1
  • Target Price
  • CASH $69.00
  • SUPN $36.00
  • AVG Volume (30 Days)
  • CASH 215.4K
  • SUPN 417.3K
  • Earning Date
  • CASH 10-23-2024
  • SUPN 11-04-2024
  • Dividend Yield
  • CASH 0.25%
  • SUPN N/A
  • EPS Growth
  • CASH 10.60
  • SUPN 130.79
  • EPS
  • CASH 6.62
  • SUPN 1.07
  • Revenue
  • CASH $712,044,000.00
  • SUPN $651,972,000.00
  • Revenue This Year
  • CASH N/A
  • SUPN $7.82
  • Revenue Next Year
  • CASH $5.04
  • SUPN N/A
  • P/E Ratio
  • CASH $11.95
  • SUPN $33.74
  • Revenue Growth
  • CASH 10.60
  • SUPN 6.79
  • 52 Week Low
  • CASH $46.68
  • SUPN $25.53
  • 52 Week High
  • CASH $83.83
  • SUPN $39.37
  • Technical
  • Relative Strength Index (RSI)
  • CASH 63.65
  • SUPN 56.91
  • Support Level
  • CASH $77.97
  • SUPN $34.86
  • Resistance Level
  • CASH $83.83
  • SUPN $36.50
  • Average True Range (ATR)
  • CASH 2.16
  • SUPN 1.65
  • MACD
  • CASH -0.03
  • SUPN -0.14
  • Stochastic Oscillator
  • CASH 73.31
  • SUPN 46.46

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly-owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer, Commercial and Corporate Services/Other. The majority of the revenue is generated from Consumer segment.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: